aminoguanidine and diabetic mice

Doug Skrecky (
Tue, 8 Sep 1998 19:53:14 -0700 (PDT)

Friedman EA. Distant DA. Fleishhacker JF. Boyd TA. Cartwright K. Institution
Department of Medicine, State University of New York, Health Science Center at Brooklyn, 11203-2098, USA. Title
Aminoguanidine prolongs survival in azotemic-induced diabetic rats. Source
American Journal of Kidney Diseases. 30(2):253-9, 1997 Aug. Abstract
Toxic effects of hyperglycemia-induced advanced glycosylated end products (AGEs) may explain some vasculopathic complications of diabetes. Aminoguanidine, a known inhibitor of AGE formation, was administered by gavage to Sprague-Dawley streptozotocin-induced diabetic rats made azotemic by surgical reduction of renal mass. All rats became hyperglycemic. Renal ablation caused renal insufficiency, as evidenced by markedly reduced endogenous creatinine clearances at days 7 and 14. Aminoguanidine-treated rats had significantly (P < 0.04) superior survival to that of untreated azotemic diabetic rats. We infer from the extended life in a rat model of uremia in diabetic nephropathy that aminoguanidine may prove beneficial in human diabetes.